- Report of Foreign Issuer (6-K)
August 10 2009 - 5:10AM
Edgar (US Regulatory)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For the month of August 2009
Commission File Number: 000-51440
CHINA MEDICAL TECHNOLOGIES, INC.
(Translation of registrants name into
English)
No. 24 Yong Chang North Road
Beijing Economic-Technological Development Area
Beijing 100176
Peoples Republic of China
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F
X
Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if
the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
No
X
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):
82-
N/A
CHINA MEDICAL TECHNOLOGIES, INC.
Form 6-K
TABLE OF CONTENTS
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
|
|
CHINA MEDICAL TECHNOLOGIES, INC
|
|
|
By:
|
|
/s/ Takyung (Sam) Tsang
|
Name:
|
|
Takyung (Sam) Tsang
|
Title:
|
|
Chief Financial Officer
|
Date: August 10, 2009
3
Exhibit 99.9
China Medical Technologies Announces Change of Independent Auditors
Beijing, August 7, 2009 China Medical Technologies, Inc. (the Company) (Nasdaq: CMED), a leading China-based medical device company that
develops, manufactures and markets advanced in-vitro diagnostic products, today announced the appointment of PricewaterhouseCoopers (PwC) as the Companys independent registered public accounting firm. PwC replaces the
Companys previous independent auditors, KPMG.
The appointment of PwC in replacement of KPMG has been approved by the Companys Audit Committee
and the Board of Directors. Upon the appointment, PwC will commence the annual audit work and is working with the Company and KPMG to ensure a seamless transition. PwC has communicated with the Companys Audit Committee and the independent law
firm engaged by the Audit Committee regarding the recent independent internal investigation before accepting this appointment. The Company expects to meet the deadline of filing its annual report on Form 20-F for the fiscal year ended March 31,
2009 before September 30, 2009.
We would like to thank KPMG for their dedicated service over the past five years, said Mr. Sam
Tsang, Chief Financial Officer of the Company. However, we believe that PwC will provide our shareholders with the best combination of cost and quality going forward. We also expect that PwC will provide fresh insights to the Company to
enhance our internal controls over financial reporting. We look forward to working with the PwC team.
The Company and KPMG have not had any
disagreement on matters of accounting principles or practices, financial statement disclosure, or auditing scope or procedures for which disagreement, if not resolved to the satisfaction of KPMG, would have caused KPMG to make reference to the
subject matter of the disagreement in connection with its report on the Companys consolidated financial statements.
About China Medical
Technologies, Inc.
China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets advanced in-vitro
diagnostic (IVD) products using Enhanced Chemiluminescence (ECLIA) technology, Fluorescent
in situ
Hybridization (FISH) technology and Surface Plasmon Resonance (SPR) technology to detect and monitor various diseases and disorders. For more
information, please visit
http://www.chinameditech.com
.
Safe Harbor Statement
This press release contains forward-looking statements. These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as will,
expects, anticipates, future, intends, plans, believes, estimates and similar statements. Such statements involve certain risks and uncertainties that could cause
actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in the Companys filings with the U.S. Securities and Exchange Commission, including its annual
report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
For more information, please contact:
Sam Tsang
Tel: 852-2511-9808
Email:
IR@chinameditech.com
4
China Medical (NASDAQ:CMED)
Historical Stock Chart
From Jun 2024 to Jul 2024
China Medical (NASDAQ:CMED)
Historical Stock Chart
From Jul 2023 to Jul 2024